alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5570 Hypodermic single lumen needle. ( a ) *Identification.* A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.
( b ) *Classification.* Class II (performance standards).
(logo) Rialto CAPITAL

 

**2016 Annual Statement of ServicerCompliance (Item 1123)**

 

               

Pooling and ServicingAgreement (the “Pooling and Servicing Agreement”) dated as of May1, 2015 by and among Credit Suisse First Boston Mortgage Securities Corp. asDepositor, Wells Fargo Bank, National Association as Master Servicer, RialtoCapital Advisors, LLC as Special Servicer, Park Bridge Lender Services LLC asOperating Advisor, Wells Fargo Bank, National Association as CertificateAdministrator and Wilmington Trust, National Association as Trustee relating tothe Credit Suisse First Boston Mortgage Securities Corp., CSAIL 2015-C2Commercial Mortgage Trust, Commercial Mortgage Pass-Through Certificates Series2015-C2 

**(CSAIL 2015-C2)**

 

 

The undersigned, a dulyauthorized officer of Rialto Capital Advisors, LLC, as special servicer (the“Special Servicer”) herein certifies to the following:

 

1. All servicing activitiesand performance of such servicing activities under the Pooling and ServicingAgreement are performed on behalf of the Special Servicer.

 

2. A review of the servicingactivities and performance by the Special Servicer for the period of January 1,2016 to December 31, 2016 (the “Reporting Period”) in accordancewith the Pooling and Servicing Agreement has been conducted under my supervision.

 

3. To the best of myknowledge, based on such review, the Special Servicer has fulfilled all of itsobligations under the terms of the Pooling and Servicing Agreement, in all materialrespects for the Reporting Period and if there has been a failure to fulfillany such obligations in any material respect, each failure and the nature andstatus thereof has been specifically identified herein.

 

 

Certified by: /s/ Adam Singer

Adam Singer, Managing Director

Date: March 1, 2017
EXHIBIT 32



SECTION 1350 CERTIFICATION





In connection with the quarterly report of InZon Corporation (formerly W-J International, Ltd.) (Company) on Form 10-QSB for the quarter ended March 31, 2008 as filed with the Securities and Exchange Commission (Report), the undersigned, in the capacities and on the dated indicated below, hereby certify pursuant to Section 906 of the Sarbanes-Oxley Act of 2003 (18 U.S.C. Section 1350) that to their knowledge:



1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





|                    |     |                                     
|------------------- | --- | ------------------------------------
|Dated: May 20, 2008 | By: | /s/ Sidney Camper III               
|                    |     | Sidney Camper III,
President        
|                    |     | Principal Executive Officer         
|                    |     |                                     
|                    |     |                                     
|Dated: May 20, 2008 | By: | /s/ Richard Dea                     
|                    |     | Richard Dea,
Chief Financial Officer
§ 884.1560 Fetal blood sampler. ( a ) *Identification.* A fetal blood sampler is a device used to obtain fetal blood transcervically through an endoscope by puncturing the fetal skin with a short blade and drawing blood into a heparinized tube. The fetal blood pH is determined and used in the diagnosis of fetal distress and fetal hypoxia.
( b ) *Classification.* Class II (performance standards).
Exhibit 31.a

I, John P. Manning, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Affordable Housing II Limited Partnership;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



1. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
2. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
3. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and





1. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



1. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
2. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.





|Date: November 19, 2004 | /s/ John P. Manning        
|----------------------- | ---------------------------
|                        | John P. Manning            
|                        | Principal Executive Officer
|                        |                            
|                        |                            
|                        |
Exhibit 10.2a

Under the 2003 CEO Variable Incentive Plan, the Human Resources Committee of the
Pinnacle West Board of Directors, annually establishes the participation level
and establishes certain financial and operational goals. However, the
calculation and the amount of payment, if any, under this Plan are in the sole
discretion of the Human Resources Committee. Accordingly, achievement of
financial and operational goals is just one method that may be utilized to
measure performance.
----

----

| Nissan Auto Receivables Owner Trust (NAROT) |
|---------------------------------------------|
| Nissan Auto Receivables 2012-B (NAR 12-B)   |
| Nissan Auto Receivables 2013-A (NAR 13-A)   |
| Nissan Auto Receivables 2013-B (NAR 13-B)   |
| Nissan Auto Receivables 2013-C (NAR 13-C)   |
| Nissan Auto Receivables 2014-A (NAR 14-A)   |
| Nissan Auto Receivables 2014-B (NAR 14-B)   |
| Nissan Auto Receivables 2015-A (NAR 15-A)   |
| Nissan Auto Receivables 2015-B (NAR 15-B)   |
| Nissan Auto Receivables 2015-C (NAR 15-C)   |
| Nissan Auto Receivables 2016-A (NAR 16-A)   |
| Nissan Auto Receivables 2016-B (NAR 16-B)   |
| Nissan Auto Receivables 2016-C (NAR 16-C)   |
| Nissan Auto Receivables 2017-A (NAR 17-A)   |
| Nissan Auto Lease Trust (NALT)             |
|--------------------------------------------|
| Nissan Auto Lease Trust 2014-A (NALT 14-A) |
| Nissan Auto Lease Trust 2014-B (NALT 14-B) |
| Nissan Auto Lease Trust 2015-A (NALT 15-A) |
| Nissan Auto Lease Trust 2015-B (NALT 15-B) |
| Nissan Auto Lease Trust 2016-A (NALT 16-A) |
| Nissan Auto Lease Trust 2016-B (NALT 16-B) |

----
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3570 OTC denture repair kit. ( a ) *Identification.* An OTC denture repair kit is a device consisting of a material, such as a resin monomer system of powder and liquid glues, that is intended to be applied permanently to a denture to mend cracks or breaks. The device may be available for purchase over-the counter.
( b ) *Classification.* Class II. The OTC denture repair kit is exempt from premarket notification procedures in subpart E of part 807 of this chapter, subject to § 872.9. The special controls for this device are FDA's: ( 1 ) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ” and
( 2 ) “OTC Denture Reliners, Repair Kits, and Partially Fabricated Denture Kits.”
[52 FR 30097, Aug. 12, 1987, as amended at 65 FR 17144, Mar. 31, 2000; 83 FR 11145, Mar. 14, 2018]
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported) December 21, 2001

                        Investment Properties Associates
                        --------------------------------
             (Exact name of registrant as specified in its charter)

         New York                        0-5537                 13-2647723
         --------                        ------                 ----------
(State or other jurisdiction          (Commission            (IRS Employer
     of incorporation)                File Number)           Identification No.)

60 East 42nd Street, New York, New York                           10165
---------------------------------------                           -----
(Address of principal executive offices)                        (Zip Code)

Registrant's telephone number, including area code (212) 687-6400

           ___________________________________________________________
          (Former name or former address, if changed since last report)


<PAGE>

ITEM 5. OTHER EVENTS.

The Registrant will make a dividend of approximately $410,000 to its general and
special limited partners and holders of record as of the close of business on
December 31, 2001 of its participations of limited partnership interests from
its operating revenue. In accordance with the Registrant's partnership
agreement, one-half of the net proceeds will be distributed to the general and
special limited partners and one-half to the holders of its participations of
limited partnership interests. It is anticipated that such dividend will be
approximately $0.25 per participation of limited partnership interest and will
be paid on March 31, 2002.


<PAGE>

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            INVESTMENT PROPERTIES ASSOCIATES

                                            BY: /s/ Irving Schneider
                                                -----------------------
                                                Name:  Irving Schneider
                                                Title: General Partner

Date: December 28, 2001
Exhibit 32.1
Certification Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934
     In connection with the quarterly report on Form 10-Q (the “Report”) ofYoubet.com, Inc. (the “Company”) for the period ended June 30, 2004, as filedwith the Securities and Exchange Commission as of the date hereof (the“Report”), I, Charles F. Champion, Chief Executive Officer of the Company, andI, Charles R. Bearchell, Chief Financial Officer of the Company, herebycertify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, that:
     (1) the Report fully complies with the requirements of Section 13(a) ofthe Securities Exchange Act of 1934, as amended; and
     (2) the information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.       August 13, 2004 By: /s/ Charles F. Champion     Charles F. Champion     President and Chief Executive Officer       August 13, 2004 By: /s/ Charles R. Bearchell     Charles R. Bearchell     Chief Financial Officer
A signed original of this written statement required by Section 906, or otherdocumentation authenticating, acknowledging, or otherwise adopting thesignature that appears in typed form within the electronic version of thiswritten statement required by Section 906, has been provided to Youbet.com,Inc. and will be retained by Youbet.com, Inc. and furnished to the Securitiesand Exchange Commission or its staff upon request.
This certification “accompanies” the Quarterly Report on Form 10-Q to which itrelates, is not deemed filed with the Securities and Exchange Commission, andis not to be incorporated by reference into any filing of the Company under theSecurities Act of 1933, as amended, or the Securities Exchange Act of 1934, asamended (whether made before or after the date of the Quarterly Report on Form10-Q, irrespective of an general incorporation language contained in suchfiling).
----

----

|   | EXHIBIT 32.1 |
|--------|--------------|

|   | 1. | I have reviewed the Report; |
|--------|----|-----------------------------|

|   | 2. | based on my knowledge, the Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Report; and |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | based on my knowledge, the financial statements, and other financial information included in the Report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in the Report. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----
§ 74.1203 FD&C Green No. 3. ( a ) *Identity and specifications.* ( 1 ) The color additive FD&C Green No. 3 shall conform in identity and specifications to the requirements of § 74.203(a)(1) and (b).
( 2 ) Color additive mixtures for drug use made with FD&C Green No. 3 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( b ) *Uses and restrictions.* The color additive FD&C Green No. 3 may be safely used for coloring drugs generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of FD&C Green No. 3 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 52144, Nov. 19, 1982]
#### § 820.140 Handling.

Each manufacturer shall establish and maintain procedures to ensure that mixups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling.
<SEQUENCE>4
<FILENAME>doc4.txt
							              Exhibit 4.1

							  SUBSCRIPTION FOR SHARES


TO:	The Board of Directors of
	PENN BIOTECH INC.
	(the "Company")

The undersigned hereby subscribes for 15,000,000 Common Shares
without par value in  the  capital  of  the  Company  and encloses
herewith the payment of $15,000 payable to the Company in respect
of such shares.

The share certificate should be made out to:

	Name:		Jai Woo Lee

	Address:	419-8 Sadang-dong, Dongjak-gu
			Seoul, Korea







DATED as of the 31st day of December 2002.




	/s/
Jai Woo Lee



WARNING:

The  Company  Act (British Columbia)  requires  that  shares  be
fully paid upon subscription.   Therefore  you  should  deposit
the  subscription  price in the Company's bank account and retain
a copy of your cancelled cheque as evidence of payment.
# C_2016007EN.01002602.xml

| 11.1.2016 | EN | Official Journal of the European Union | C 7/26 |
| --- | --- | --- | --- |

11.1.2016

EN

Official Journal of the European Union

C 7/26

---

Judgment of the General Court of 18 November 2015 — Research Engineering & Manufacturing v OHIM — Nedschroef Holding (TRILOBULAR)

(Case T-558/14) (1)

1

((Community trade mark - Invalidity proceedings - Community word mark TRILOBULAR - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009 - Article 52(1)(a) of Regulation No 207/2009))

(2016/C 007/36)

Language of the case: English

Parties

Parties

Applicant: Research Engineering & Manufacturing, Inc. (Middletown, Rhode Island, United States) (represented by: S. Malynicz, G. Hollingworth, Barristers, K. Gilbert and M. Gilbert, Solicitors)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: M. Rajh, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Nedschroef Holding BV (Helmond, Netherlands)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 12 May 2014 (Case R 442/2013-4), relating to invalidity proceedings between Nedschroef Holding BV and Research Engineering & Manufacturing, Inc.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Research Engineering & Manufacturing, Inc., to bear the costs. |
| --- | --- |

2.

Orders Research Engineering & Manufacturing, Inc., to bear the costs.

---

(1)  OJ C 351, 6.10.2014.

1

---
§ 1309.43 Suspension or revocation of registration. ( a ) The Administrator may suspend any registration pursuant to section 304(a) of the Act (21 U.S.C. 824(a)) for any period of time he determines.
( b ) The Administrator may revoke any registration pursuant to section 304(a) of the Act (21 U.S.C. 824(a)).
( c ) Before revoking or suspending any registration, the Administrator shall issue an order to show cause pursuant to Section 1309.46 and, if requested by the registrant, shall hold a hearing pursuant to Section 1309.51. Notwithstanding the requirements of this Section, however, the Administrator may suspend any registration pending a final order pursuant to § 1309.44.
( d ) Upon service of the order of the Administrator suspending or revoking registration, the registrant shall immediately deliver his or her Certificate of Registration to the nearest office of the Administration. Also, upon service of the order of the Administrator revoking or suspending registration, the registrant shall, as instructed by the Administrator: ( 1 ) Deliver all List I chemicals in his or her possession that were obtained under the authority of a registration or an exemption from registration granted by the Administrator by regulation, to the nearest office of the Administration or to authorized agents of the Administration; or
( 2 ) Place all such List I chemicals in his or her possession under seal as described in section 304(f) of the Act (21 U.S.C. 824(f)).
( e ) In the event that revocation or suspension is limited to a particular chemical or chemicals, the registrant shall be given a new Certificate of Registration for all substances not affected by such revocation or suspension; no fee shall be required for the new Certificate of Registration. The registrant shall deliver the old Certificate of Registration to the nearest office of the Administration. Also, upon service of the order of the Administrator revoking or suspending registration with respect to a particular chemical or chemicals, the registrant shall, as instructed by the Administrator: ( 1 ) Deliver to the nearest office of the Administration or to authorized agents of the Administration all of the particular chemical or chemicals in his or her possession that were obtained under the authority of a registration or an exemption from registration granted by the Administrator by regulation, which are affected by the revocation or suspension; or
( 2 ) Place all of such chemicals under seal as described in section 304(f) of the Act (21 U.S.C. 824(f)).
[60 FR 32454, June 22, 1995, as amended at 62 FR 5916, Feb. 10, 1997]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.3500 Polytetrafluoroethylene with carbon fibers composite implant material. ( a ) *Identification.* A polytetrafluoroethylene with carbon fibers composite implant material is a porous device material intended to be implanted during surgery of the chin, jaw, nose, or bones or tissue near the eye or ear. The device material serves as a space-occupying substance and is shaped and formed by the surgeon to conform to the patient's need.
( b ) *Classification.* Class II.
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3810 Root canal post. ( a ) *Identification.* A root canal post is a device made of austenitic alloys or alloys containing 75 percent or greater gold and metals of the platinum group intended to be cemented into the root canal of a tooth to stabilize and support a restoration.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 60 FR 38900, July 28, 1995; 66 FR 38798, July 25, 2001]